FILTER
LATEST ARTICLES
Expanding Mining Frontiers in West Africa
October 02, 2020
The under-explored gold-bearing grounds of West Africa are the “last frontier” in the gold space.
The State of Gabon’s Oil Industry
September 09, 2020
Gabon’s maturing fields and decreasing production levels, together with the low price regime over the past five years, have brought the country’s oil industry to a turning point.
2020: Nigeria - The Year of Natural Gas
August 11, 2020
Nigeria has enormous potential to diversify the economy away from crude oil, which has overshadowed the gas in Nigeria’s oil and gas industry. The country is struggling to exploit its natural gas resources which rank among the 10 largest worldwide.”
Chemical Distribution in Latin America
July 16, 2020
The distribution market has always been very fragmented in the region, but M&A has been gathering pace in past years.
Turkey Pharmaceuticals: Bringing All Actors Together
June 17, 2020
Industry, university, investors - the two-way bridge to the knowledge gap.
Nigeria: The Champion of Local Content
June 17, 2020
The Nigerian Oil and Gas Development Act of 2010 imposed local content requirements that have been largely successful and have benefitted both the Nigerian population and the industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
